Effects of XXXX soluble @entity9820 on experimental @entity631 .

@entity1 @entity32 @entity8 @entity38867 @entity548 @entity9820 @entity35 @entity715 @entity631
BACKGROUND: Coagulation and @entity32 are both important processes that contribute to @entity8 . The present study was performed to evaluate the effects of recombinant @entity1 soluble @entity9820 (RHS-TM) in a lethal model of @entity631 and to investigate the possible mechanisms. METHODS: Thrombotic @entity631 was induced in @entity35 by administration of lipopolysaccharide and rabbit anti-rat glomerular basement membrane antibody. One hour later, RHS-TM or heparin was administered, and the histological findings, renal functions, and coagulation parameters were evaluated. To evaluate the contribution of @entity38867 ( @entity38867 ) to the results obtained in @entity35 treated with RHS-TM, plasma @entity38867 levels were measured. Then, carboxypeptidase inhibitor (CPI), which prevents the function of @entity38867 , was administered. RESULTS: Massive @entity8 and @entity548 developed within five hours of disease induction, and all @entity35 died within 24 hours. RHS-TM (3 mg/kg) prevented the progression of the disease and all @entity35 survived. Heparin (250 U/kg/h) showed similar anti- @entity715 effect, but induced @entity548 in the lungs or stomach. RHS-TM attenuated leukocyte/neutrophil infiltration in the glomerulus but heparin did not, suggesting that RHS-TM has anti-inflammatory properties. @entity38867 levels in plasma were about threefold higher in @entity35 treated with RHS-TM compared to those in @entity35 treated with heparin. Furthermore, the inhibitory effect of RHS-TM on leukocyte/neutrophil infiltration was significantly diminished by injection of CPI. CONCLUSION: RHS-TM effectively attenuates the injuries of @entity631 in @entity35 . The results indicate that RHS-TM, in addition to its anti- @entity715 action, may exert its anti-inflammatory properties by converting proCPR to @entity38867 , which then inactivates anaphylatoxins. RHS-TM is a potential novel therapeutic tool for @entity8 .
